Stock Track | Hims & Hers Stock Soars on Stellar Q3 Results, Weight Loss Drug Prospects

Stock Track

Nov 06, 2024

Shares of telehealth platform Hims & Hers Health Inc. (HIMS) skyrocketed by 5.62% on November 6, 2024, riding high on the company's robust third-quarter earnings and promising growth plans in the lucrative weight loss drug market.

The company reported a remarkable 77% year-over-year surge in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. This stellar performance was fueled by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like the popular semaglutide.

Adding to the positive momentum, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a widely used diabetes and weight loss medication, on its platform by 2025. This strategic move is expected to further bolster the company's revenue and growth prospects in the burgeoning weight management market, which has excited investors and contributed to the stock's upward surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1191939682"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191939682\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191939682?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191939682","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Stock Soars on Stellar Q3 Results, Weight Loss Drug Prospects","media":"Stock Track","content":"<p>Shares of telehealth platform Hims & Hers Health Inc. (HIMS) skyrocketed by 5.62% on November 6, 2024, riding high on the company's robust third-quarter earnings and promising growth plans in the lucrative weight loss drug market.</p>\n\n<p>The company reported a remarkable 77% year-over-year surge in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. This stellar performance was fueled by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like the popular semaglutide.</p>\n\n<p>Adding to the positive momentum, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a widely used diabetes and weight loss medication, on its platform by 2025. This strategic move is expected to further bolster the company's revenue and growth prospects in the burgeoning weight management market, which has excited investors and contributed to the stock's upward surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Stock Soars on Stellar Q3 Results, Weight Loss Drug Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Stock Soars on Stellar Q3 Results, Weight Loss Drug Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-06 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of telehealth platform Hims & Hers Health Inc. (HIMS) skyrocketed by 5.62% on November 6, 2024, riding high on the company's robust third-quarter earnings and promising growth plans in the lucrative weight loss drug market.</p>\n\n<p>The company reported a remarkable 77% year-over-year surge in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. This stellar performance was fueled by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like the popular semaglutide.</p>\n\n<p>Adding to the positive momentum, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a widely used diabetes and weight loss medication, on its platform by 2025. This strategic move is expected to further bolster the company's revenue and growth prospects in the burgeoning weight management market, which has excited investors and contributed to the stock's upward surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1191939682","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191939682","pubTimestamp":1730904031,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of telehealth platform Hims & Hers Health Inc.  skyrocketed by 5.62% on November 6, 2024, riding high on the company's robust third-quarter earnings and promising growth plans in the lucrative weight loss drug market.The company reported a remarkable 77% year-over-year surge in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. This stellar performance was fueled by strong demand for Hims & Hers' personalized weight loss solutions, particularly its c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票追踪Hims&Hers股价因第三季度业绩出色和减肥药前景而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of telehealth platform Hims & Hers Health Inc. (HIMS) skyrocketed by 5.62% on November 6, 2024, riding high on the company's robust third-quarter earnings and promising growth plans in the lucrative weight loss drug market.\nThe company reported a remarkable 77% year-over-year surge in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. This stellar performance was fueled by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like the popular semaglutide.\nAdding to the positive momentum, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a widely used diabetes and weight loss medication, on its platform by 2025. This strategic move is expected to further bolster the company's revenue and growth prospects in the burgeoning weight management market, which has excited investors and contributed to the stock's upward surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}